1. Home
  2. LIDR vs KPTI Comparison

LIDR vs KPTI Comparison

Compare LIDR & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AEye Inc.

LIDR

AEye Inc.

HOLD

Current Price

$2.21

Market Cap

118.0M

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.78

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIDR
KPTI
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.0M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
LIDR
KPTI
Price
$2.21
$6.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$6.00
$22.17
AVG Volume (30 Days)
1.5M
174.4K
Earning Date
11-06-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$182,000.00
$142,530,000.00
Revenue This Year
$2.76
$3.82
Revenue Next Year
$2,830.58
$3.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$3.51
52 Week High
$6.44
$12.45

Technical Indicators

Market Signals
Indicator
LIDR
KPTI
Relative Strength Index (RSI) 38.15 63.89
Support Level $2.30 $5.70
Resistance Level $2.79 $7.48
Average True Range (ATR) 0.17 0.45
MACD -0.02 0.16
Stochastic Oscillator 0.85 69.78

Price Performance

Historical Comparison
LIDR
KPTI

About LIDR AEye Inc.

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: